Wong V, de Boer R, Baron-Hay S, Blum R, et al. Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer. Clin Breast Cancer 2022 Aug 30. pii: S1526-8209(22)00188.
PMID: 36151018